Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NRG-GI002
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
- NCT02921256 ↗
- Completed
- National Cancer Institute (NCI)
- Deep
We haven't built an HCP commentary report on NRG-GI002 (veliparib; pembrolizumab in locally advanced rectal adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NRG-GI002 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 22 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Rectal Adenocarcinoma; Stage II Rectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7
- Interventions
- Capecitabine; Fluorouracil; Intensity-Modulated Radiation Therapy; Leucovorin; Oxaliplatin; Pembrolizumab; Veliparib
- Arms
- Arm I (mFOLFOX6, RT, capecitabine) · Active comparator
- Arm II (mFOLFOX6, RT, capecitabine, veliparib) · Experimental
- Arm III (mFOLFOX6, RT, capecitabine, pembrolizumab) · Experimental
- Enrollment
- 363
- Primary outcomes
- Neoadjuvant Rectal Cancer (NAR) Score
- Sponsor
- National Cancer Institute (NCI) with NRG Oncology
- Start
- Jan 11, 2017
- Primary completion
- Apr 21, 2020
- Results posted
- Yes
- Registry record
- NCT02921256 · updated Dec 4, 2025
Publications
linked from the registry- Hall WA, Li J, You YN, Gollub MJ, Grajo JR, Rosen M, dePrisco G, Yothers G, Dorth JA, Rahma OE, Russell MM, Gross HM, Jacobs SA, Faller BA, George S, Al Baghdadi T, Haddock MG, Valicenti R, Hong TS, George TJ. Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma. J Clin Oncol. 2023 Oct 10;41(29):4643-4651. doi: 10.1200/JCO.22.02525. Epub 2023 Jul 21. PubMed 37478389
- Rahma OE, Yothers G, Hong TS, Russell MM, You YN, Parker W, Jacobs SA, Colangelo LH, Lucas PC, Gollub MJ, Hall WA, Kachnic LA, Vijayvergia N, O'Rourke MA, Faller BA, Valicenti RK, Schefter TE, George S, Kainthla R, Stella PJ, Sigurdson E, Wolmark N, George TJ. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Aug 1;7(8):1225-1230. doi: 10.1001/jamaoncol.2021.1683. PubMed 34196693